{"id":"ranibizumab-lucentis","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Conjunctival hemorrhage"},{"rate":"5-10","effect":"Eye pain"},{"rate":"5-10","effect":"Floaters"},{"rate":"5-10","effect":"Intraocular pressure elevation"},{"rate":"0.05-0.1","effect":"Endophthalmitis"},{"rate":"0.1-0.5","effect":"Retinal detachment"}]},"_chembl":{"chemblId":"CHEMBL1201825","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ranibizumab is a recombinant humanized monoclonal antibody fragment (Fab) that specifically targets and neutralizes VEGF-A, a key driver of pathological neovascularization and vascular permeability in retinal diseases. By blocking VEGF-A signaling, it prevents the formation of abnormal blood vessels and reduces fluid leakage, thereby slowing or halting vision loss in retinal conditions. It is administered via intravitreal injection directly into the eye to achieve high local concentrations.","oneSentence":"Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and leakage in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:19.377Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neovascular (wet) age-related macular degeneration"},{"name":"Macular edema following retinal vein occlusion"},{"name":"Diabetic macular edema"},{"name":"Diabetic retinopathy"},{"name":"Myopic choroidal neovascularization"}]},"trialDetails":[{"nctId":"NCT07007065","phase":"PHASE3","title":"Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-11-05","conditions":"Neovascular Age-related Macular Degeneration","enrollment":561},{"nctId":"NCT06176352","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-03-06","conditions":"Choroidal Neovascularization Secondary to Pathologic Myopia","enrollment":280},{"nctId":"NCT05476926","phase":"","title":"A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-11-21","conditions":"Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion","enrollment":6000},{"nctId":"NCT05217680","phase":"PHASE3","title":"Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2021-05-24","conditions":"Diabetic Macular Edema","enrollment":510},{"nctId":"NCT04853251","phase":"PHASE4","title":"A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2021-12-14","conditions":"Neovascular Age-related Macular Degeneration","enrollment":188},{"nctId":"NCT04108156","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-09-30","conditions":"Diabetic Macular Edema","enrollment":634},{"nctId":"NCT04514653","phase":"PHASE2","title":"RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-08-25","conditions":"Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":146},{"nctId":"NCT06847542","phase":"PHASE3","title":"A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-11-27","conditions":"Neovascular Age-related Macular Degeneration","enrollment":250},{"nctId":"NCT03683251","phase":"PHASE3","title":"Extension Study for the Port Delivery System With Ranibizumab (Portal)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-09-20","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":1000},{"nctId":"NCT04503551","phase":"PHASE3","title":"A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-08-10","conditions":"Diabetic Retinopathy","enrollment":174},{"nctId":"NCT04704921","phase":"PHASE2, PHASE3","title":"Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD","status":"RECRUITING","sponsor":"AbbVie","startDate":"2020-12-29","conditions":"AMD, nAMD, Wet Age-related Macular Degeneration","enrollment":630},{"nctId":"NCT04657289","phase":"PHASE3","title":"A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-07-14","conditions":"Neovascular Age-related Macular Degeneration (nAMD)","enrollment":451},{"nctId":"NCT07389577","phase":"PHASE3","title":"A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD)","status":"COMPLETED","sponsor":"Jecho Biopharmaceuticals Co., Ltd.","startDate":"2022-03-01","conditions":"Wet Age-related Macular Degeneration","enrollment":443},{"nctId":"NCT04567303","phase":"PHASE1, PHASE2","title":"Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-10-28","conditions":"Macular Degeneration","enrollment":177},{"nctId":"NCT05562947","phase":"PHASE3","title":"A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-06-17","conditions":"Neovascular Age-related Macular Degeneration, nAMD","enrollment":68},{"nctId":"NCT04690556","phase":"PHASE3","title":"Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD","status":"COMPLETED","sponsor":"Lupin Ltd.","startDate":"2020-09-14","conditions":"Neovascular Age-related Macular Degeneration","enrollment":600},{"nctId":"NCT06957080","phase":"PHASE2, PHASE3","title":"A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME","status":"ACTIVE_NOT_RECRUITING","sponsor":"EyeBiotech Ltd.","startDate":"2025-04-16","conditions":"Diabetic Macular Edema (DME)","enrollment":1054},{"nctId":"NCT05520177","phase":"PHASE3","title":"A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss","status":"COMPLETED","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2022-12-27","conditions":"Branch Retinal Vein Occlusion","enrollment":351},{"nctId":"NCT07269769","phase":"PHASE3","title":"A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD","status":"NOT_YET_RECRUITING","sponsor":"Tasly Pharmaceutical Group Co., Ltd","startDate":"2026-01-01","conditions":"AMD","enrollment":450},{"nctId":"NCT05439629","phase":"PHASE3","title":"Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2022-07-07","conditions":"Neovascular (Wet) Age-related Macular Degeneration","enrollment":488},{"nctId":"NCT07258108","phase":"PHASE2","title":"Lucentis Plus Tagolimumab in PD-L1+, HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-11-21","conditions":"Breast Cancer","enrollment":35},{"nctId":"NCT00527475","phase":"PHASE2","title":"Ranibizumab and Reduced Fluence PDT for AMD","status":"COMPLETED","sponsor":"Texas Retina Associates","startDate":"2007-05","conditions":"Macular Degeneration","enrollment":60},{"nctId":"NCT07249216","phase":"NA","title":"Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting","status":"RECRUITING","sponsor":"Singapore National Eye Centre","startDate":"2025-07-18","conditions":"Age Related Macular Degeneration","enrollment":117},{"nctId":"NCT06952452","phase":"PHASE3","title":"Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)","status":"RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2022-11-18","conditions":"Wet Age-related Macular Degeneration","enrollment":630},{"nctId":"NCT03161652","phase":"PHASE2","title":"Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema","status":"RECRUITING","sponsor":"Carmen Clapp","startDate":"2017-05-24","conditions":"Diabetic Macular Edema, Diabetic Retinopathy","enrollment":120},{"nctId":"NCT05151731","phase":"PHASE2","title":"A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-12-31","conditions":"Diabetic Macular Edema","enrollment":394},{"nctId":"NCT05151744","phase":"PHASE2","title":"A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-12-17","conditions":"Diabetic Macular Edema","enrollment":187},{"nctId":"NCT05407636","phase":"PHASE3","title":"Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD","status":"RECRUITING","sponsor":"AbbVie","startDate":"2022-01-13","conditions":"AMD, nAMD, Wet Age-related Macular Degeneration","enrollment":660},{"nctId":"NCT06985706","phase":"PHASE3","title":"Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns","status":"RECRUITING","sponsor":"Belfast Health and Social Care Trust","startDate":"2025-05-19","conditions":"Severe Diabetic Macular Oedema","enrollment":264},{"nctId":"NCT03832179","phase":"PHASE4","title":"Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification","status":"COMPLETED","sponsor":"Bay Area Retina Associates","startDate":"2018-11-15","conditions":"Diabetic Macular Edema, Cataract","enrollment":16},{"nctId":"NCT06234514","phase":"PHASE4","title":"Manage Macular Cystoid Edema With Retinal Vein Obstruction Using Traditional Chinese Medicine and Ranibizumab","status":"COMPLETED","sponsor":"Dongyang People's Hospital","startDate":"2023-01-01","conditions":"Macular Cystoid Edema","enrollment":111},{"nctId":"NCT06571045","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME","status":"ACTIVE_NOT_RECRUITING","sponsor":"EyeBiotech Ltd.","startDate":"2024-08-07","conditions":"Diabetic Macular Edema (DME)","enrollment":984},{"nctId":"NCT02243878","phase":"PHASE3","title":"Stereotactic Radiotherapy for Wet AMD (STAR)","status":"COMPLETED","sponsor":"King's College Hospital NHS Trust","startDate":"2014-12","conditions":"Neovascular (Wet) Age-related Macular Degeneration (AMD)","enrollment":411},{"nctId":"NCT04757610","phase":"PHASE3","title":"OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)","status":"TERMINATED","sponsor":"Opthea Limited","startDate":"2021-03-12","conditions":"Neovascular Age-related Macular Degeneration","enrollment":986},{"nctId":"NCT05304949","phase":"","title":"Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-06-22","conditions":"Retinopathy of Prematurity","enrollment":69},{"nctId":"NCT04667910","phase":"PHASE2","title":"601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)","status":"COMPLETED","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2021-01-27","conditions":"Central Retinal Vein Occlusion","enrollment":60},{"nctId":"NCT04667897","phase":"PHASE2","title":"601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)","status":"COMPLETED","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2021-01-28","conditions":"Branch Retinal Vein Occlusion","enrollment":60},{"nctId":"NCT03362190","phase":"PHASE2","title":"ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2017-10-11","conditions":"Neovascular Age-related Macular Degeneration","enrollment":64},{"nctId":"NCT07009574","phase":"","title":"The Treatment Burden of Myopic Choroidal Neovascularization","status":"NOT_YET_RECRUITING","sponsor":"Policlinico Gaspare Rodolico - San Marco Catania","startDate":"2025-06-01","conditions":"Myopic Choroidal Neovascularisation, Anti-VEGF Treatment, Burden","enrollment":100},{"nctId":"NCT06305416","phase":"PHASE3","title":"A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema","status":"RECRUITING","sponsor":"Incepta Pharmaceuticals Ltd","startDate":"2024-03-30","conditions":"Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema","enrollment":70},{"nctId":"NCT03585556","phase":"PHASE1","title":"AAVCAGsCD59 for the Treatment of Wet AMD","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-09-13","conditions":"Wet Age-related Macular Degeneration","enrollment":25},{"nctId":"NCT04444492","phase":"PHASE3","title":"Combination of Ranibizumab and Targeted Laser Photocoagulation","status":"RECRUITING","sponsor":"University of Giessen","startDate":"2020-08-25","conditions":"Central Retinal Vein Occlusion With Macular Edema","enrollment":110},{"nctId":"NCT05576792","phase":"","title":"A 24-week Study Evaluating the Effectiveness and Safety of Lucentis® 0.2mg in Retinopathy of Prematurity Participants in China","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-01-13","conditions":"Retinopathy of Prematurity","enrollment":62},{"nctId":"NCT05003245","phase":"PHASE3","title":"Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2021-11-01","conditions":"Age Related Macular Degeneration","enrollment":407},{"nctId":"NCT02397954","phase":"PHASE2","title":"A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2015-03-12","conditions":"Idiopathic Polypoidal Choroidal Vasculopathy","enrollment":4},{"nctId":"NCT03844074","phase":"PHASE3","title":"A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Outlook Therapeutics, Inc.","startDate":"2018-10-01","conditions":"Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration","enrollment":61},{"nctId":"NCT03834753","phase":"PHASE3","title":"A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Outlook Therapeutics, Inc.","startDate":"2019-06-25","conditions":"Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration","enrollment":228},{"nctId":"NCT05571267","phase":"PHASE2","title":"Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD","status":"TERMINATED","sponsor":"IVERIC bio, Inc.","startDate":"2016-10-20","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":1},{"nctId":"NCT00709527","phase":"PHASE1","title":"ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2008-10-16","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":60},{"nctId":"NCT06190093","phase":"PHASE3","title":"A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Outlook Therapeutics, Inc.","startDate":"2024-01-24","conditions":"Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration","enrollment":400},{"nctId":"NCT06841250","phase":"","title":"Early Changes in OCT Biomarkers After the First Intravitreal Anti-VEGF Injection in Treatment-naïve DME","status":"ENROLLING_BY_INVITATION","sponsor":"Sohag University","startDate":"2025-01-16","conditions":"Early OCT Biomarker Changes in Response to Anti-VEGF","enrollment":50},{"nctId":"NCT05640895","phase":"","title":"Intravitreal Injection Site and Perceived Pain","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2022-11-14","conditions":"Pain","enrollment":53},{"nctId":"NCT06271330","phase":"","title":"Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD.","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-04-01","conditions":"Age-related Macular Degeneration","enrollment":100},{"nctId":"NCT06771271","phase":"PHASE1","title":"A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-07-22","conditions":"Diabetic Macular Edema, Uveitic Macular Edema","enrollment":85},{"nctId":"NCT05461339","phase":"PHASE3","title":"TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioDlink Biopharm Co., Ltd.","startDate":"2022-06-28","conditions":"Neovascular Age-related Macular Degeneration","enrollment":488},{"nctId":"NCT04740671","phase":"PHASE3","title":"A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2021-07-01","conditions":"Age Related Macular Degeneration","enrollment":410},{"nctId":"NCT06176963","phase":"PHASE2","title":"A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2023-11-21","conditions":"Neovascular Age-related Macular Degeneration, Macular Edema, Retinal Vein Occlusion","enrollment":34},{"nctId":"NCT06708624","phase":"PHASE4","title":"Ocular Safety and Usability Study for FYB201 PFS","status":"COMPLETED","sponsor":"Formycon AG","startDate":"2024-06-11","conditions":"Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema","enrollment":31},{"nctId":"NCT05861466","phase":"PHASE4","title":"Comparative Study Between IVI of Ranibizumab with and Without Prior ACP in Patients with DME Using OCT-A","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-01-01","conditions":"Diabetic Macular Edema","enrollment":102},{"nctId":"NCT02669953","phase":"","title":"Aflibercept in Recurrent or Persistent CNV","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2015-12","conditions":"Age Related Macular Degeneration, Intravitreal Injections, Diabetic Macular Edema","enrollment":80},{"nctId":"NCT02302079","phase":"PHASE2","title":"A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2015-01-12","conditions":"Diabetes Mellitus, Diabetic Macular Edema","enrollment":96},{"nctId":"NCT02387957","phase":"PHASE2","title":"A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2016-04-26","conditions":"Age-Related Macular Degeneration","enrollment":63},{"nctId":"NCT01940900","phase":"PHASE3","title":"A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2013-08","conditions":"Age-Related Macular Degeneration","enrollment":627},{"nctId":"NCT01944839","phase":"PHASE3","title":"A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2013-08","conditions":"Age-Related Macular Degeneration","enrollment":619},{"nctId":"NCT03709745","phase":"PHASE4","title":"Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion","status":"COMPLETED","sponsor":"St. Erik Eye Hospital","startDate":"2018-10-18","conditions":"Branch Retinal Vein Occlusion with Macular Edema","enrollment":110},{"nctId":"NCT03630315","phase":"PHASE1","title":"CLN-0046: Treatment of AMD Subjects With OTX-TKI","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2019-02-18","conditions":"Neovascular Age-related Macular Degeneration","enrollment":29},{"nctId":"NCT03927690","phase":"PHASE2","title":"Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-24","conditions":"Diabetic Macular Edema","enrollment":91},{"nctId":"NCT04662944","phase":"","title":"A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-02-23","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":494},{"nctId":"NCT05211804","phase":"","title":"Mechanisms of Retinal Revascularization and Clinical Indicators of Neovascular AMD Relapse","status":"COMPLETED","sponsor":"Sorlandet Hospital HF","startDate":"2022-02-08","conditions":"Wet Macular Degeneration","enrollment":31},{"nctId":"NCT00930189","phase":"PHASE2, PHASE3","title":"Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization","status":"WITHDRAWN","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2006-04","conditions":"Subfoveal Choroidal Neovascularization","enrollment":""},{"nctId":"NCT04884399","phase":"PHASE1","title":"Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2021-06-03","conditions":"Wet Age-related Macular Degeneration","enrollment":24},{"nctId":"NCT04075136","phase":"PHASE4","title":"Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2023-03-30","conditions":"Exudative Age Related Macular Degeneration","enrollment":""},{"nctId":"NCT01089517","phase":"PHASE2","title":"A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2010-03","conditions":"Age-Related Macular Degeneration","enrollment":449},{"nctId":"NCT02214628","phase":"PHASE2","title":"Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2014-07","conditions":"Age-related Macular Degeneration","enrollment":101},{"nctId":"NCT00569140","phase":"PHASE1","title":"A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2007-12","conditions":"Age-related Macular Degeneration","enrollment":18},{"nctId":"NCT06231121","phase":"","title":"Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2023-12-01","conditions":"Neovascular Age-related Macular Degeneration","enrollment":13},{"nctId":"NCT05126966","phase":"PHASE3","title":"A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2023-12-29","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":""},{"nctId":"NCT06205979","phase":"EARLY_PHASE1","title":"Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2023-12-12","conditions":"Diabetic Macular Edema","enrollment":50},{"nctId":"NCT06179030","phase":"","title":"Systemic and Local Inflammatory Biomarkers in the Treatment of Refractory Diabetic Macular Edema","status":"COMPLETED","sponsor":"Saglik Bilimleri Universitesi","startDate":"2022-05-01","conditions":"Diabetic Macular Edema, Inflammation","enrollment":80},{"nctId":"NCT06173245","phase":"NA","title":"Subfoveal Choroidal Thickness and Visual Acuity After Intravitreal Injection of Ranibizumab in Diabetic Retinopathy","status":"COMPLETED","sponsor":"Egyptian Biomedical Research Network","startDate":"2021-02-01","conditions":"Subfoveal Choroidal Thickness, Intravitreal, Ranibizumab","enrollment":50},{"nctId":"NCT03805100","phase":"PHASE3","title":"Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD","status":"COMPLETED","sponsor":"Xbrane Biopharma AB","startDate":"2019-04-19","conditions":"Macular Degeneration","enrollment":582},{"nctId":"NCT04140448","phase":"","title":"Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion","status":"UNKNOWN","sponsor":"Renmin Hospital of Wuhan University","startDate":"2023-10-09","conditions":"Retinal Vein Occlusion, Macular Edema","enrollment":60},{"nctId":"NCT03784443","phase":"PHASE2, PHASE3","title":"Combined Ranibizumab and Iluvien for Diabetic Macular Oedema","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2019-09-01","conditions":"Diabetic Macular Edema, Diabetes","enrollment":""},{"nctId":"NCT05080803","phase":"","title":"Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome","status":"COMPLETED","sponsor":"European School of Advanced Studies in Ophthalmology","startDate":"2021-06-01","conditions":"Diabetic Macular Edema","enrollment":608},{"nctId":"NCT04667039","phase":"PHASE3","title":"Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®","status":"UNKNOWN","sponsor":"AO GENERIUM","startDate":"2022-03-20","conditions":"Age Related Macular Degeneration (ARMD)","enrollment":408},{"nctId":"NCT02511067","phase":"PHASE2","title":"Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2016-10-01","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT02207712","phase":"NA","title":"Noctura400 Treatment for Diabetic Retinopathy (CANDLE)","status":"TERMINATED","sponsor":"PolyPhotonix Medical","startDate":"2014-11","conditions":"Diabetic Macular Oedema","enrollment":252},{"nctId":"NCT05138029","phase":"PHASE3","title":"Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation","status":"UNKNOWN","sponsor":"Affiliated Hospital of Nantong University","startDate":"2021-11-15","conditions":"Diabetic Retinopathy","enrollment":60},{"nctId":"NCT02623426","phase":"PHASE3","title":"Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2017-03-09","conditions":"Uveitis, Macular Edema","enrollment":194},{"nctId":"NCT05815212","phase":"","title":"Ranibizumab 0.5 mg for Diabetic Macular Edema With Initial Intensive Treatment in the Real World Clinical Setting in Korea (Rising K)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-11","conditions":"Diabetic Macular Edema","enrollment":87},{"nctId":"NCT00606138","phase":"PHASE1, PHASE2","title":"Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2008-01","conditions":"Proliferative Diabetic Retinopathy","enrollment":9},{"nctId":"NCT02559180","phase":"PHASE4","title":"Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab","status":"COMPLETED","sponsor":"Rishi Singh","startDate":"2015-10","conditions":"Diabetic Retinopathy, Macular Edema","enrollment":20},{"nctId":"NCT04991350","phase":"PHASE4","title":"Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema","status":"TERMINATED","sponsor":"Cairo University","startDate":"2021-11-26","conditions":"Diabetic Macular Edema, Macular Ischemia, Diabetic Retinopathy","enrollment":5},{"nctId":"NCT05480293","phase":"PHASE3","title":"This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2023-02-14","conditions":"Wet Age-related Macular Degeneration","enrollment":446},{"nctId":"NCT02640664","phase":"PHASE3","title":"Rainbow Extension Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-06-16","conditions":"Retinopathy of Prematurity (ROP)","enrollment":180},{"nctId":"NCT05716932","phase":"","title":"Focal Laser Single Intravitreal Ranibizumab Retinal Artery Macroaneurysm.","status":"COMPLETED","sponsor":"Dar El Oyoun Hospital","startDate":"2022-12-22","conditions":"Retinal Artery Macroaneurysm","enrollment":14},{"nctId":"NCT05701124","phase":"PHASE3","title":"Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2020-11-20","conditions":"Retina Disease, Retinopathy of Prematurity, Ranibizumab","enrollment":30},{"nctId":"NCT03963596","phase":"NA","title":"Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Myopia","status":"COMPLETED","sponsor":"The Filatov Institute of Eye Diseases and Tissue Therapy","startDate":"2018-03-27","conditions":"Pathologic Myopia","enrollment":122},{"nctId":"NCT05678517","phase":"","title":"Seven-year Outcomes Following Intensive Anti-VEGF Therapy in Wet AMD","status":"COMPLETED","sponsor":"Semmelweis University","startDate":"2010-01-01","conditions":"Age-Related Macular Degeneration","enrollment":47},{"nctId":"NCT03690947","phase":"PHASE4","title":"Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME","status":"COMPLETED","sponsor":"Beijing Hospital","startDate":"2018-10-01","conditions":"Diabetic Macular Edema","enrollment":72}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CARDIAC FAILURE CONGESTIVE"},{"count":1,"reaction":"CARDIAC MURMUR"},{"count":1,"reaction":"CONDITION AGGRAVATED"},{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"FATIGUE"},{"count":1,"reaction":"FEELING ABNORMAL"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lucentis","NDC # 50242-0080-01, Brand Name is Lucentis","ranibizumab","Ranibizumab (anti-VEGF agent)","Lucentis = ranibizumab"],"phase":"marketed","status":"active","brandName":"Ranibizumab (Lucentis)","genericName":"Ranibizumab (Lucentis)","companyName":"Greater Houston Retina Research","companyId":"greater-houston-retina-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and leakage in the eye. Used for Neovascular (wet) age-related macular degeneration, Macular edema following retinal vein occlusion, Diabetic macular edema.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}